Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
salmeterol xinafoate · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| fluticasone propionate/salmeterol combination DISKUS | DRUG | - |
| salmeterol xinafoate | DRUG | - |
Inclusion criteria: * Diagnosis of COPD. Exclusion criteria: * Diagnosis of asthma or an uncontrolled medical condition or respiratory disorder other than COPD. * Other inclusion and exclusion criteria will be evaluated at the first study visit.
Salmeterol xinafoate is used for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is a small molecule respiratory therapy developed by GSK plc. The drug has been evaluated in a Phase 3 clinical trial for this condition.
Salmeterol xinafoate is a long-acting beta2-adrenergic agonist that targets beta2-adrenergic receptors in the airways. By stimulating these receptors, it promotes bronchodilation, which helps to open up the airways and improve breathing in patients with chronic obstructive pulmonary disease.
Salmeterol xinafoate is developed by GSK plc, a global pharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company has conducted clinical trials to evaluate the drug's safety and efficacy in patients with chronic obstructive pulmonary disease.
Salmeterol xinafoate is in Phase 3 clinical development. It has completed a Phase 3 trial for chronic obstructive pulmonary disease, but it remains an investigational drug and has not been approved for this indication. The completed trial involved 150 participants in Japan.
Salmeterol xinafoate has been studied in one completed Phase 3 clinical trial, identified by the National Clinical Trial number NCT00269126. This trial evaluated the drug for chronic obstructive pulmonary disease in 150 patients aged 40 years and older in Japan. The study was randomized and double-blind.
Salmeterol xinafoate is a salt form of salmeterol, a long-acting beta2-adrenergic agonist. The xinafoate salt is used to improve the drug's stability and delivery. In clinical use, salmeterol xinafoate is often referred to simply as salmeterol, but they are chemically related compounds.